


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
APPROVAL OF THE FIRST GENERIC “SITAGLIPTIN PHOSPHATE AND
METFORMIN HYDROCHLORIDE SUSTAINED-RELEASE TABLETS”
FOR MARKETING

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that “Sitagliptin Phosphate and Metformin Hydrochloride Sustained-release Tablets (西格列汀二甲雙胍緩釋片)” (Brand name: Pinduo (品多)), a drug developed by the Group for the treatment of diabetes, has obtained drug registration certificate granted by the National Medical Products Administration of the PRC. The product was filed as a Chemicals Category 3 drug and is deemed to have passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs, being the first generic drug of its kind that has been approved for marketing in the PRC.

Sitagliptin Phosphate and Metformin Hydrochloride Sustained-release Tablets are indicated for adults with type 2 diabetes who are receiving treatments in the combination of sitagliptin and metformin. Sitagliptin phosphate is an oral, highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor and metformin is a first-line drug currently recommended by diabetes medication guidelines. As the duration of treatment increases, the control rate of blood glucose will gradually decrease. Studies have shown that the combination of sitagliptin phosphate and the traditional hypoglycaemic drug metformin can improve the control rate of blood glucose without increasing adverse effects. The combination of sitagliptin and metformin is recommended by both domestic and international treatment guidelines.

Sitagliptin Phosphate and Metformin Hydrochloride Sustained-release Tablets are more convenient to take than regular tablets, as they only need to be taken once a day. The approval for launch of this product will bring a better treatment option to diabetic patients in the PRC.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 10 January 2022

As at the date of this announcement, the Board of the Company comprises nine executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.